colorectal cancer
Conditions
Interventions
None listed
Sponsors
National Research and Development Agency, National Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Eligibility criteria for the prospective cohort 1. Patients with colorectal cancer diagnosed with lung or liver metastases 2. Computed tomography (CT) scan performed within 60 days of registration 3. Patients who plan to undergo resection of lung metastasis with curative intent 4. Resection with curative intent is performed to remove primary lesions 5. 20 years or older at the time of obtaining informed consent 6. Provides written informed consent to participate in this study Eligibility criteria for the retrospective cohort 1. Patients with colorectal cancer diagnosed with lung or liver metastases 2. Prior to biobank blood sampling, resection with curative intent was performed to remove the primary lesion 3. Interval from biobank blood sampling to excision of metastatic sites was less than 90 days 4. Those who have undergone curative resection of metastasis to other organs during the study period* *Two-stage resection is acceptable in patients who have undergone curative resection. 5. Comprehensive consent for the use of surplus medical samples was obtained from the National Cancer Center.
Exclusion criteria
Exclusion criteria: Exclusion criteria for the prospective cohort 1. Active overlapping cancers noted at the time of curative resection. However, patients with a recurrence-free period of at least 5 years; those with basal cell carcinoma or spinous cell carcinoma of the skin that was eventually cured after receiving local treatment; and those with superficial bladder cancer, cervical cancer, carcinoma in situ, intramucosal cancer (that can be treated endoscopically), and nonmetastatic prostate cancer (that does not require systematic treatment) can be registered. 2. Pre-operative treatment (chemotherapy, radiation therapy, immunotherapy) is administered or planned prior to metastasis resection Exclusion criteria for the retrospective cohort 1. Active overlapping cancers noted at the time of curative resection. *However, patients with a recurrence-free period of at least 5 years or those with basal cell carcinoma or spinous cell carcinoma of the skin that was eventually cured by local treatment, superficial bladder cancer, cervical cancer, carcinoma in situ (that can be treated endoscopically), and nonmetastatic prostate cancer (that does not require systematic treatment) can be registered. 2. Pre-operative treatment (chemotherapy, radiation therapy, immunotherapy) was administered prior to the curative resection of metastases. **Adjuvant chemotherapy administered prior to the appearance of metastases is acceptable.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlations between pathological features and status of ctDNA detection in tissue samples of metastatic organs Correlations between ctDNA detection status and clinical information, including radiological images Significance of exosome analysis in cases in which ctDNA is difficult to detect | — |
Countries
Japan
Contacts
Public ContactHiroki Yukami
National Cancer Center Hospital East Department of Gastroenterology and Gastrointestinal Oncology
Outcome results
None listed